Xospata 40 mg film-coated tablets

  • Name:

    Xospata 40 mg film-coated tablets

  • Company:
    info
  • Active Ingredients:

    Gilteritinib

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 11/01/21

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 11/1/2021
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

Click on this link to Download PDF directly

Astellas Pharma Co. Ltd

Astellas Pharma Co

Company Products

Medicine NameActive Ingredients
Medicine Name Advagraf Prolonged-Release Capsules Active Ingredients Tacrolimus Monohydrate
Medicine Name Betmiga 25mg and 50mg prolonged-release tablets Active Ingredients Mirabegron
Medicine Name Eligard 22.5mg Active Ingredients Leuprorelin Acetate
Medicine Name Eligard 45mg Active Ingredients Leuprorelin Acetate
Medicine Name Eligard 7.5mg Active Ingredients Leuprorelin Acetate
Medicine Name Modigraf 0.2mg & 1mg granules for oral suspension Active Ingredients Tacrolimus Monohydrate
Medicine Name Omnexel Active Ingredients Tamsulosin Hydrochloride
Medicine Name Prograf Capsules Active Ingredients Tacrolimus Monohydrate
Medicine Name Prograf Concentrate for Infusion Active Ingredients Tacrolimus
Medicine Name Vesitirim 1 mg/ml oral suspension Active Ingredients Solifenacin succinate
Medicine Name Vesitirim 10mg Film-coated Tablets Active Ingredients Solifenacin succinate
Medicine Name Vesitirim 5mg Film-Coated tablets Active Ingredients Solifenacin succinate
Medicine Name Vesomni 6 mg/0.4 mg modified release tablets Active Ingredients Solifenacin succinate, Tamsulosin Hydrochloride
Medicine Name Xospata 40 mg film-coated tablets Active Ingredients Gilteritinib
Medicine Name Xtandi 40 mg film-coated tablets Active Ingredients enzalutamide
1 - 0 of 15 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 8 March 2021 Ed-HCP

Reasons for updating

  • Add New Doc

Updated on 8 March 2021 Ed-Ptnt

Reasons for updating

  • Add New Doc

Updated on 11 January 2021 SPC

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 11 January 2021 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects

Updated on 18 February 2020 PIL

Reasons for updating

  • Change to section 4 - how to report a side effect

Updated on 14 February 2020 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 14 February 2020 PIL

Reasons for updating

  • New PIL for new product
  • HCP Educational Information Brochure - Differentiation syndromeRisk Minimisation Materials

    files-icon(Click to Download)